Authors : Aditya Maurya; Aditya Tripathi; Afsana Khatoon; Aishwarya Singh; Sandeep Kumar Singh

Volume/Issue : Volume 9 - 2024, Issue 9 - September

Google Scholar : https://tinyurl.com/55uwm85f

Scribd : https://tinyurl.com/yj783fys

DOI : https://doi.org/10.38124/ijisrt/IJISRT24SEP329

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : One of the key forces influencing the advancement of pharmaceuticals, biotechnology, and pharmacology is the drug industry. The process of finding and creating medications is known as drug discovery. It is a procedure designed to find a substance that has therapeutic value in treating and curing illness. The identification of candidates, synthesis, characterisation, screening, and tests for therapeutic efficacy are all steps in the drug discovery process.A chemical will start the drug development process before going through clinical trials if its efficacy in these tests has been demonstrated. Despite encouraging discoveries and billions dollar investments, the process of developing a new drug is a time-consuming and costly endeavor that is now experiencing a crisis. Currently, only roughly 400 distinct pharmacological targets are targeted by all of the available medicines combined. It is predicted that the number of possible therapeutic targets that could be used in future drug therapy is at least ten times higher.The process of finding a chemical that has therapeutic potential for treating and curing disease is known as drug discovery. Candidate identification, synthesis, characterisation, validation, optimization, screening, and tests for therapeutic efficacy are all steps in this process.Following a compound's demonstration of relevance in theseresearch, the drug discovery process will development before going through clinical trials. A treatment that satisfies all regulatory standards and is safe and effective must go through multiple stages of the new drug development process.Our article's overarching thesis is that the procedure is drawn out, costly, and complex enough that numerous biological targets must be taken into account before a new drug is finally approved for clinical usage, and new research instruments might be required to look into each one.

Keywords : Drug Discovery; Drug Development; Clinical Trials; Potential Drug Targets; Clinical Trial

References :

1. Shayne CG. Introduction: drug Discovery in the 21stCentury. Drug Discovery Handbook, Wiley Press, 2005; 1-10.
2. Smith GC, OíDonnel JT. The Process of New Drug Discovery and Development, Eds., 2^nd edition, Informa Healthcare, New York 2006.
3. Moffat J, Vincent F, Lee J, Eder J, Prunotto M. Opportunities and Challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017; 16(8):531-543.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new Estimates of drug development costs. Journal of Health Economics, 2003; 151-185.
5. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good Drug target. Drug Discovery Today, 2012; 17:S24-S30.
6. Lindsay MA. Target discovery. Nature Reviews Drug Discovery, 2003; 2:831–838.
7. Terstappen G, Schlüpen, C, Raggiaschi R, Gaviraghi G. Target Deconvolution strategies in drug discovery. Nature Reviews Drug Discovery, 2007; 6(11):891-903.
8. Peet NP. What constitutes target validation? Targets. 2003; 2:125–127.
9. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and Number of drug targets. Nature Reviews Drug Discovery, 2006; 5:821-834.
10. Odilia Osakwe. Social Aspects of Drug Discovery, Development and Commercialization. Chapter 6 Preclinical In Vitro Studies: Development and Applicability. Elsevier. 2016.
11. Croston G. The utility of target-based discovery. Expert Opinion on Drug Discovery, 2017; 12(5):427-429.
12. Henning SW, Beste G. Loss-of-function strategies in drug target Validation. Current Drug Discovery Technology, 2002; 17–21.
13. John GH, Martyn NB, Bristol-Myers S. High throughput screening for Lead discovery. Burger‗s Medicinal Chemistry and Drug Discovery, 6^Th Edition, Drug Discovery and Drug Development, Wiley Press, 2002; 2:37-70.
14. Patidar AK, Selvam G, Jeyakandan M, Mobiya AK, Bagherwal A, Sanadya G, Mehta R. Lead Discovery and lead optimization: A useful Strategy in molecular modification of lead compound in analog design. International journal of drug design and discovery. 2011; 2(2):458-463.
15. Huber W. A new strategy for improved secondary screening and lead Optimization using high-resolution SPR characterization of compound– Target interactions. J Mol. Recogn. 2005; 18:273–281.
16. Lofas S. Optimizing the hit-to-lead process using SPR analysis. Assay Of Drug Development Technologies, 2004; 2:407-416.
17. Barile FA. Pri. Nciples of Toxicological Testing. CRC Press, USA, 2008.
18. Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical Trials. 4^th ed. New York: Springer Science and Business Media LLC; 2010.
19. Faqi AS. A comprehensive guide to toxicology in preclinical drug Development. Waltham, MA: Elsevier; 2013.
20. Vogel HG. Drug Discovery and Evaluation 2^nd edition. Springer, USA, 2002.
21. Karara AH, Edeki T, McLeod J, et al. PhRMA survey on the conduct Of first-in-human clinical trials under exploratory investigational new Drug applications. Journal of ClinicalPharmacology, 2010; 50:380–391.
22. Fitzpatrick S. The clinical trial protocol. Buckinghamshire: Institute of Clinical Research; 2005.
23. Kinders, Robert, et al. Phase 0 Clinical Trials in Cancer Drug Development: From FDA.
24. DiMasi J. Risks in New Drug Development: Approval success Rates For Investigational Drugs. Clinical Pharmacology & Therapeutics, 2001; 297-307.
25. Friedhoff L. New Drugs: An Insider‘s Guide to the FDA‘s New Drug Approval Process for Scientists, Investors and Patients. New York, NY: PSPG Publishing; 2009.
26. FDA, The FDA and the Drug Development Process: How the FDA Insures that drugs are safe and effective, FDA Fact sheet, 2002.
27. Adams CP, and Brantner VV. New Drug Development: Estimating Entry from human clinical trials. Bureau of Economics Federal Trade Commission. 2003.
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and Computational approaches to estimate solubility and permeability In drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
29. Luscombe NM, Greenbaum D, Gerstein M. What is bioinformatics? A proposed definition and overview of the field. Methods Inf Med 2001;40:346-58.
30. Manly CJ, Louise-May S, Hammer JD. The impact of informatics and Computational chemistry on synthesis and screening. Drug Discov Today 2000;6:1101-10.
31. Meyer AY, Richards WG. Similarity of molecular shape. J Comput Aided Mol Design 1991;5:427-36.
32. Meyer EF, Swanson SM, Williams JA. Molecular modelling and drug Design. Pharmacol Ther 2000;85:113-21.
33. Mulholland AJ, Grant GH, Richards WG. Computer modelling of enzyme Catalysed reaction mechanisms. Protein Eng 1993;6:133-9.
34. Oprea T.I., Bologa C.G., Brunak S., Campbell A., Gan G.N., Gaulton A., Gomez S.M., Guha R., Hersey A., Holmes J., et al. Unexplored therapeutic opportunities in the human genome. Nat. Rev. Drug Discov. 2018;17:317–332. Doi: 10.1038/nrd.2018.14. [PMC free article] [PubMed] [CrossRef] [Google Scholar]